핵의학

본문글자크기
  • 2019년 01월호
    [J Clin Med.] PET으로 결핵치료반응평가 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Treatment Response of Pulmonary Multidrug-Resistant Tuberculosis.

    성균관의대 / 최준영, 전병우, 고원중*

  • 출처
    J Clin Med.
  • 등재일
    2018 Dec 17
  • 저널이슈번호
    7(12). pii: E559. doi: 10.3390/jcm7120559.
  • 내용

    바로가기  >

    Abstract
    BACKGROUND:
    The purpose of this prospective study was to evaluate the role of 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for assessing treatment response in patients with pulmonary multidrug-resistant tuberculosis (MDR-TB).

    METHODS:
    The study subjects were four patients diagnosed with pulmonary MDR-TB who underwent MDR-TB treatment and serial 18F-FDG PET/CT at baseline and 6 and 12 months after treatment. The highest lung maximum standardized uptake value (SUVmax), average SUVmean (average of all hypermetabolic parenchymal lesions), total metabolic lung volume (TMLV, sum of metabolic volumes from the hypermetabolic parenchymal lesions), and total lung glycolysis (TLG, sum of lesion glycolysis from the hypermetabolic parenchymal lesions) were determined as representative quantitative PET parameters for each patient.

    RESULTS:
    All patients except one had negative sputum culture conversion after one month of treatment and achieved successful treatment outcomes. Baseline TMLV and TLG PET parameters were much higher in the single patient with treatment failure than in the remaining three patients with treatment success. No other PET parameters at baseline or follow-up were associated with the treatment results.

    CONCLUSIONS:
    Pretreatment volume-based 18F-FDG PET/CT lung parameters were associated with the final therapeutic response in patients with pulmonary MDR-TB. Our preliminary results warrant a larger study.

     


    Author information

    Choi JY1, Jhun BW2, Hyun SH3, Chung MJ4, Koh WJ5.
    1
    Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. jynm.choi@samsung.com.
    2
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnamgu, Seoul 06351, Korea. byungwoo.jhun@gmail.com.
    3
    Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. shnm.hyun@samsung.com.
    4
    Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. mjchung@skku.edu.
    5
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnamgu, Seoul 06351, Korea. wjkoh@skku.edu.

  • 키워드
    18F-FDG; Multidrug-resistant tuberculosis; PET/CT; Pulmonary tuberculosis; Therapeutic response
  • 편집위원

    꼭 종양만이 아닌 양성 질환에서의 PET 적용분야 확장에 도움이 될 것으로 판단됨. (실제 임상에서도 흉부CT에서는 비활동성 결핵이라고 했으나 PET에서 섭취가 있으면 활동성으로 인정하는 경향임.)

    덧글달기2019-01-23 14:23:58

  • 덧글달기
    덧글달기
       IP : 18.221.236.224

    등록